TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1507816
Drug: Disopyramide (intravenous)
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide (intravenous)
Study: 1507816
Drug: Ajmaline (intravenous)
Normalized name: ajmaline
DrugBank: Ajmaline (DB01426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ajmaline (intravenous)
Study: 1507816
Drug: Verapamil (intravenous)
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (intravenous)
Study: 1507816
Drug: Novocaine amide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novocaine amide (intravenous)
Study: 1507816
Drug: Ethacizin (intravenous)
Normalized name: ethacizine
DrugBank: Ethacizine (DB13645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethacizin (intravenous)
Study: 1507816
Drug: Quinidine (oral)
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine (oral)
Study: 1507816
Drug: Kinilentin (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinilentin (oral)
Study: 1507816
Drug: Disopyramide (oral)
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide (oral)
Study: 1507816
Drug: Propranolol (oral)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (oral)
Study: 1507816
Drug: Mexitil (oral)
Normalized name: mexiletine hydrochloride Oral Capsule [Mexitil]
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mexitil (oral)
Study: 1507816
Drug: Overall efficacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall efficacy of antiarrhythmic therapy
Study: 6343416
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg/h)
Study: 6343416
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (6.5 ml/h)
Study: 24569914
Drug: Z-100 at
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-100 at 0.2 µg (Z)
Study: 23122972
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine dosing strategies (80% of usual dose, call physician for dose, refer to dosing table)
Study: 23122972
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus bolus group (dosing table strategy)
Study: 23122972
Drug: Insulin glargine‐only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glargine‐only group
Study: 23122972
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus bolus group
Study: 7032305
Drug: Blank rotating
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank rotating disk (same duration as treatment group)
Study: 7032305
Drug: Weekly acuity
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly acuity evaluation without treatment (second control group)
Study: 30665198
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy (MT) directed at the right-side ankle and foot
Study: 30665198
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (CONTROL group)
Study: 22134226
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (primarily vapocoolant spray)
Study: 19138437
Drug: High fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fish oil (HFO) meal (2.2 g fish oil)
Study: 19138437
Drug: Reference (REF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference (REF) meal (0.3 g fish oil)
Study: 15539706
Drug: Thiotepa (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotepa (15 mg on days 1, 3, and 5 after percutaneous pericardiocentesis)
Study: 11394556
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi exercise program (6 months, twice per week for 60 min)
Study: 9480997
Drug: beclomethasone three
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone three times daily
Study: 9480997
Drug: theophylline twice
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: theophylline twice daily
Study: 7818840
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive therapy (diuretics or beta-blockers)
Study: 30980399
Drug: Sorafenib (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (lower dose)
Study: 30980399
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxychloroquine and sorafenib
Study: 23256574
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch 1 - 3 mg/24 h
Study: 18438227
Drug: Pre-exercise energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exercise energy supplement (combination of branched chain amino acids, creatine, taurine, caffeine, and glucuronolactone)
Study: 18438227
Drug: Pre-exercise energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exercise energy supplement
Study: 12907538
Drug: Sequential i.v./po
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential i.v./po moxifloxacin monotherapy (400 mg qd)
Study: 12907538
Drug: i.v./po co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v./po co-amoxiclav (1.2 g i.v./625 mg po tid) with or without clarithromycin (500 mg bid)
Study: 10200750
Drug: Enhanced acute-phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced acute-phase treatment for depression
Study: 10200750
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment for depression
Study: 7634752
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of insulin-like growth factor I (30 micrograms h-1 kg-1) and insulin (0.23 nmol h-1 kg-1)
Study: 7634752
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of insulin-like growth factor I (5 micrograms h-1 kg-1) and insulin (0.04 nmol h-1 kg-1)
Study: 2694482
Drug: Mefloquine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine alone (250 mg/week)
Study: 2694482
Drug: Mefloquine, sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine, sulfadoxine (500 mg/week), and pyrimethamine (25 mg/week) (MSP)
Study: 793186
Drug: Ketoprofen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (2 X 50 mg daily)
Study: 793186
Drug: Phenylbutazone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (2 X 300 mg daily)
Study: 29738183
Drug: Lamiophlomis Rotata
Normalized name: Phlomoides rotata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamiophlomis Rotata Capsule (LRC) at 3 capsules tid for 4 weeks
Study: 29738183
Drug: Lamiophlomis Rotata
Normalized name: Phlomoides rotata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamiophlomis Rotata Capsule (LRC) at 3 capsules tid after 4 weeks of treatment
Study: 29738183
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd after 4 weeks of treatment
Study: 21441550
Drug: Etanercept (TNF-α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (TNF-α inhibitor)
Study: 21441550
Drug: Infliximab (TNF-α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (TNF-α inhibitor)
Study: 15187323
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer laser treatment with different initial UV doses, treated twice a week for up to 30 sessions.
Study: 15187323
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer laser treatment for acral and joint areas.
Study: 11502230
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose drink
Study: 11502230
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose drink (informed)
Study: 11502230
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose drink (misinformed)
Study: 8064736
Drug: Zinc acexamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc acexamate (ZAC) 300 mg
Study: 31706786
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lurasidone (80mg)
Study: 31706786
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose lurasidone (240mg)
Study: 17268411
Drug: Lutein 18
Normalized name: lutein 18.6 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein 18 mg
Study: 17268411
Drug: Lutein 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein 36 mg
Study: 11376504
Drug: PDA (Automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA (Automated Protamine Dose Assay)
Study: 11376504
Drug: Empirical protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical protamine ratio (1 mg protamine/100 U heparin)
Study: 11376504
Drug: PDA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA and ACT after protamine administration
Study: 7945787
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge with aspirin
Study: 7945787
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge with sulfites
Study: 7945787
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge with NSAIDs or food and drug additives
Study: 28843136
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for BED
Study: 21057697
Drug: Desmopressin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.4 microg/kg after administration of protamine (group C)
Study: 21057697
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet therapy (group A)
Study: 21057697
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg qd (group B)
Study: 21057697
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg qd (group C)
Study: 17922971
Drug: FEV(1) >
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEV(1) > 2 L
Study: 15727952
Drug: Troglitazone (PPARgamma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (PPARgamma agonist), 5 microM palmitate, chronic treatment for 4 days
Study: 15727952
Drug: Troglitazone (PPARgamma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (PPARgamma agonist)
Study: 31900172
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of primaquine (0.5 mg/kg/day)
Study: 23488362
Drug: Post-discharge telephone
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discharge telephone intervention delivered weekly for the first month and then monthly until the third month (experimental group)
Study: 18617627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise training and weight loss (WLEX; n = 17)
Study: 18617627
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (EX; n = 36) and Combination (WLEX; n = 17)
Study: 16210715
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid supplementation initiated during the first trimester with 30 mg Fe plus 175 microg folic acid
Study: 16210715
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid supplementation initiated during the first trimester with 60 mg Fe plus 350 microg folic acid
Study: 16210715
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid supplementation initiated at week 20 with 30 mg Fe plus 175 microg folic acid
Study: 16210715
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid supplementation initiated at week 20 with 60 mg Fe plus 350 microg folic acid
Study: 12821469
Drug: Gentamicin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (3 mg/kg/day intravenously for 14 days) and Doxycycline (200 mg/day orally for 28 days)
Study: 11143912
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy for PLB
Study: 11143912
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy for ESNHL
Study: 11143912
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy for SLB
Study: 8841903
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of 2 or more modes
Study: 8841903
Drug: various modes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: various modes of oral hygiene education
Study: 1617028
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg methylprednisolone in 10 ml NaCl 0.9% (corticoid group)
Study: 1617028
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml NaCl (NaCl group)
Study: 6541715
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml of essential amino acids
Study: 6541715
Drug: Normal postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal postoperative electrolyte solutions alone
Study: 30212981
Drug: AML/VAL 5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: AML/VAL 5/160 mg FDC
Study: 30212981
Drug: VAL/HCTZ 160/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAL/HCTZ 160/12.5 mg FDC
Study: 26704145
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a drop of sterile nonpreserved 0.9% sodium chloride solution
Study: 24251556
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT group)
Study: 22088556
Drug: AZD3480 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 (5 mg, 20 mg, and 35/100 mg depending on CYP2D6 metabolic status)
Study: 21053620
Drug: Haloperidol and
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol and trihexyphenidyl (Western medicine group)
Study: 12165970
Drug: 4-week stress
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week stress management treatment
Study: 1759830
Drug: Ceftibuten (CFB)
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten (CFB) single oral dose of 4.5 or 9.0 mg/kg
Study: 6818599
Drug: Test dose
Normalized name: Epinephrine/Lidocaine Hydrochloride Epidural Kit [ANESTHESIA TRAY (W/TEST DOSE)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dose of ethanol
Study: 30669469
Drug: 140 g
Normalized name: STEARIC ACID 1 g in 140 g TOPICAL LIQUID [Body Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 g of whole blueberries
Study: 30669469
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (matched for calories, sugars, and fiber)
Study: 17878209
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with methotrexate and ciclosporine
Study: 17878209
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with methotrexate and placebo-ciclosporine
Study: 12605235
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil 0.05 mg
Study: 12605235
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil 0.1 mg
Study: 12605235
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil 0.2 mg
Study: 12605235
Drug: Topical alprostadil
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alprostadil 0.3 mg
Study: 10838535
Drug: Cardioplegic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioplegic group with 42 mmol/L glucose and 10 IU/L insulin
Study: 10838535
Drug: Cardioplegic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioplegic group with 84 mmol/L glucose and 10 IU/L insulin
Study: 10838535
Drug: Cardioplegic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioplegic group with 42 mmol/L glucose without insulin
Study: 10838535
Drug: Cardioplegic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioplegic group with 84 mmol/L glucose without insulin
Study: 8482629
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy doses of < or = 54 Gy
Study: 8482629
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy doses > or = 57.6 Gy
Study: 8482629
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy doses > or = 63 Gy
Study: 8482629
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy doses 57.6 Gy with a boost of 63 Gy
Study: 8482629
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation above 63 Gy at 1.8 Gy per day
Study: 28975842
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care including weekly group exercise
Study: 15580967
Drug: Opegan (Santen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opegan (Santen Pharmaceuticals, Osaka, Japan)
Study: 9228196
Drug: Atropine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (15 microg/kg i.v. loading dose followed by 0.15 microg/kg/min by i.v. infusion) with Noradrenaline (5 incremental doses of 10‐120 ng/kg/min)
Study: 9228196
Drug: Atropine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (15 microg/kg i.v. loading dose followed by 0.15 microg/kg/min by i.v. infusion) with Tyramine (4 incremental doses of 5‐20 microg/kg/min)
Study: 9228196
Drug: Noradrenaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (5 incremental doses of 10‐120 ng/kg/min)
Study: 9228196
Drug: Tyramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine (4 incremental doses of 5‐20 microg/kg/min)
Study: 7962379
Drug: Buserelin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin, 500 micrograms subcutaneously daily, with variable amounts of menopausal gonadotrophins for ovarian stimulation.
Study: 31558426
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (n=42)
Study: 25197669
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU r-LH for 4 days followed by 400 IU r-FSH after downregulation with daily GnRh agonist
Study: 22803101
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with mesalazine
Study: 22803101
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with mesalazine and dalargin
Study: 19565392
Drug: Traditional dysarthria
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dysarthria therapy
Study: 16307694
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg at week 0 and week 2, followed by either placebo or infliximab (5 or 10 mg/kg) every 8 weeks or episodically on loss of response.
Study: 16307694
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment (5 or 10 mg/kg)
Study: 12004211
Drug: Inulin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (24 g daily for 3 weeks)
Study: 10460604
Drug: Treatment-related mortality
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-related mortality during induction and first remission of AML
Study: 1164639
Drug: Clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clobetasone butyrate 0.05% ointment and cream
Study: 30476460
Drug: 16.2 g
Normalized name: DODECYLBENZENESULFONIC ACID 16.2 g in 1 L TOPICAL SOLUTION [Opti Blue]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.2 g (270 mg I/mL)
Study: 30476460
Drug: 16.0 g
Normalized name: Glycerin 16.0 g in 200 mL TOPICAL GEL [Aloe Soothing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.0 g (320 mg I/mL)
Study: 30476460
Drug: DECTA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: DECTA (both doses)
Study: 28528472
Drug: Daily assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily assay of serum calcium and phosphorus (Control)